The pharmaceuticals CEO that raised the cost of a drug used by Aids sufferers by more than 5,000 per cent also hiked the price of medication taken by children for a rare kidney disease, it has emerged.
The pharmaceuticals CEO that raised the cost of a drug used by Aids sufferers by more than 5,000 per cent also hiked the price of medication taken by children for a rare kidney disease, it has emerged.